We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The researchers hope to determine whether the drug improves blood oxygen levels and reduces mortality as well as time spent in an intensive care unit. Read More
Despite announcing positive results for its phase 2/3 COVID-19 antibody cocktail trial Thursday, a potential safety signal has led Regeneron to temporarily stop enrolling patients who require high-flow oxygen or mechanical ventilation. Read More
Data from Regeneron’s phase 2/3 trial of its COVID-19 antibody cocktail showed the treatment significantly reduced viral load and the number of medical visits needed by nonhospitalized patients, the company said Thursday. Read More
Moderna is still on track to file for Emergency Use Authorization (EUA) for its COVID-19 vaccine in the later part of November and is currently gearing up for worldwide distribution. Read More
The U.S. government has struck a $375 million deal with Eli Lilly for 300,000 vials of its investigational COVID-19 treatment, LY-CoV555 (bamlanivimab). Read More
The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) has halted a clinical trial evaluating Eli Lilly’s investigational monoclonal antibody, LY-CoV555 (bamlanivimab), in combination with remdesivir for the treatment of COVID-19 patients. Read More
Novavax has announced that it will start a late-stage clinical trial of its investigational COVID-19 vaccine in the U.S. by the end of November. Read More
Pfizer CEO Albert Bourla announced Tuesday that the company won’t have the necessary phase 3 trial data required to submit its COVID-19 vaccine candidate for Emergency Use Authorization (EUA) this month, despite previous projections. Read More